12,015 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by LM Advisors LLC

LM Advisors LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,015 shares of the biopharmaceutical company’s stock, valued at approximately $1,110,000.

Other hedge funds have also modified their holdings of the company. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter worth about $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $31,000. Finally, Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 1.3 %

GILD stock opened at $109.27 on Thursday. The company has a market capitalization of $136.08 billion, a PE ratio of 295.32, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm’s 50-day moving average is $104.69 and its 200 day moving average is $94.46.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.89%. Gilead Sciences’s dividend payout ratio is 854.05%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GILD shares. Piper Sandler increased their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Morgan Stanley raised their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Finally, Wells Fargo & Company boosted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 in the last three months. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.